{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:12:36Z","timestamp":1777497156425,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100016345","name":"Renmin Hospital of Wuhan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010846","name":"Health and Family Planning Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013807","name":"Wuhan University School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.rbmo.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T03:29:02Z","timestamp":1602646142000},"page":"291-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model"],"prefix":"10.1016","volume":"42","author":[{"given":"Jin","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianrong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingzhen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2020.10.006_bib0001","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0301-2115(99)00082-2","article-title":"Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome","volume":"87","author":"Aboulghar","year":"1999","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0002","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.mehy.2007.11.004","article-title":"Is vascular endothelial growth factor (VEGF) the main mediator in ovarian hyperstimulation syndrome (OHSS)?","volume":"70","author":"Ajonuma","year":"2008","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/(SICI)1098-2795(199811)51:3<287::AID-MRD8>3.0.CO;2-L","article-title":"Regulation of follicular luteinization by a gonadotropin-releasing hormone agonist: relationship between steroidogenesis and apoptosis","volume":"51","author":"Andreu","year":"1998","journal-title":"Mol. Reprod. Dev."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0004","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1093\/humrep\/deq080","article-title":"Maternal death related to IVF in the Netherlands 1984-2008","volume":"25","author":"Braat","year":"2010","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0005","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1210\/endo.143.4.8726","article-title":"Caspase-3 is a pivotal mediator of apoptosis during regression of the ovarian corpus luteum","volume":"143","author":"Carambula","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0006","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejogrb.2013.12.001","article-title":"A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model","volume":"174","author":"Cenksoy","year":"2014","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0007","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1360\/03yc9029","article-title":"Expression of apoptosis-related genes Fas\/FasL, Bax\/Bcl-2 and Caspase-3 in rat corpus luteum during luteal regression","volume":"46","author":"Chen","year":"2003","journal-title":"Sci. China C Life Sci."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0008","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.mce.2013.12.009","article-title":"Luteinizing hormone and human chorionic gonadotropin: origins of difference","volume":"383","author":"Choi","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0009","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00313029500169273","article-title":"A fatal case of ovarian hyperstimulation syndrome with cerebral infarction","volume":"27","author":"Cluroe","year":"1995","journal-title":"Pathology"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.fertnstert.2003.06.016","article-title":"Value of the serum estradiol level for preventing ovarian hyperstimulation syndrome: a retrospective case control study","volume":"81","author":"D'Angelo","year":"2004","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0011","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0015-0282(00)00670-1","article-title":"Role of vascular endothelial growth factor in ovarian physiology and pathology","volume":"74","author":"Geva","year":"2000","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-0030-1265670","article-title":"Physiology and pathology of ovarian hyperstimulation syndrome","volume":"28","author":"Gomez","year":"2010","journal-title":"Semin Reprod. Med."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0013","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1196\/annals.1386.022","article-title":"Aromatase inhibitors: structural features and biochemical characterization","volume":"1089","author":"Hong","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0014","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1093\/humrep\/dew149","article-title":"Ovarian hyperstimulation syndrome: review and new classification criteria for reporting in clinical trials","volume":"31","author":"Humaidan","year":"2016","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1507\/endocrj.50.515","article-title":"Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats","volume":"50","author":"Ishikawa","year":"2003","journal-title":"Endocr. J."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0016","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.fertnstert.2012.05.042","article-title":"Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women","volume":"98","author":"Jayaprakasan","year":"2012","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0017","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jgyn.2016.04.002","article-title":"Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome","volume":"46","author":"Jellad","year":"2017","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0018","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1001\/jama.2014.14488","article-title":"National ART Surveillance System (NASS) Group. Safety of assisted reproductive technology in the United States, 2000-2011","volume":"313","author":"Kawwass","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0019","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1080\/09513590.2016.1188376","article-title":"The combination of Everolimus with Verapamil reduces ovarian weight and vascular permeability on ovarian hyperstimulation syndrome: a preclinical experimental randomized controlled study","volume":"32","author":"Kitsou","year":"2016","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fertnstert.2003.05.032","article-title":"Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome","volume":"81","author":"Kol","year":"2004","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0021","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/GCO.0000000000000284","article-title":"Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome","volume":"28","author":"Kwik","year":"2016","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0022","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/1471-0528.12572","article-title":"Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome","volume":"121","author":"Lainas","year":"2014","journal-title":"BJOG"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0023","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1477-7827-10-69","article-title":"Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study","volume":"10","author":"Lainas","year":"2012","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0024","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1472-6483(10)60366-5","article-title":"Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist","volume":"15","author":"Lainas","year":"2007","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0025","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0026","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0029-7844(95)00456-4","article-title":"Elevated interleukin-6 levels in the ovarian hyperstimulation syndrome: ovarian immunohistochemical localization of interleukin-6 signal","volume":"87","author":"Loret de Mola","year":"1996","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0027","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.fertnstert.2009.05.092","article-title":"Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome","volume":"94","author":"Luke","year":"2010","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2016.08.018","article-title":"Effect of letrozole on moderate and severe early-onset ovarian hyperstimulation syndrome in high-risk women: a prospective randomized trial","volume":"216","author":"Mai","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0029","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a008656","article-title":"Caspase functions in cell death and disease","volume":"5","author":"McIlwain","year":"2013","journal-title":"Cold Spring Harb Perspect Biol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0030","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/uog.14684","article-title":"Ovarian hyperstimulation syndrome: pathophysiology, staging, prediction and prevention","volume":"45","author":"Nastri","year":"2015","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0031","doi-asserted-by":"crossref","first-page":"c319","DOI":"10.1159\/000322830","article-title":"Sample size calculations","volume":"118","author":"Noordzij","year":"2011","journal-title":"Nephron Clin. Pract."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0303-7207(03)00061-3","article-title":"Ovarian hyperstimulation syndrome-model rats; the manifestation and clinical implication","volume":"202","author":"Ohba","year":"2003","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0033","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.fertnstert.2016.08.048","article-title":"Electronic address, A. a. o., Practice Committee of the American Society for Reproductive, M. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline","volume":"106","year":"2016","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0034","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1080\/15384101.2015.1033593","article-title":"Involvement of atypical transcription factor E2F8 in the polyploidization during mouse and human decidualization","volume":"14","author":"Qi","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/humupd\/3.3.255","article-title":"The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome","volume":"3","author":"Rizk","year":"1997","journal-title":"Hum. Reprod. Update"},{"key":"10.1016\/j.rbmo.2020.10.006_bib0036","first-page":"659","article-title":"The corpus luteum: determinants of progesterone secretion in the normal menstrual cycle","volume":"71","author":"Soules","year":"1988","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0037","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.fertnstert.2013.12.026","article-title":"Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles","volume":"101","author":"Steward","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0038","doi-asserted-by":"crossref","first-page":"949","DOI":"10.3109\/09513590.2015.1077218","article-title":"Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist","volume":"31","author":"Taskin","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.rbmo.2020.10.006_bib0039","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum. Reprod."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147264832030571X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147264832030571X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:19:23Z","timestamp":1761466763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147264832030571X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S147264832030571X"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2020.10.006","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of GnRH-antagonist, mifepristone and letrozole on preventing ovarian hyperstimulation syndrome in rat model","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}